UK must reform drug pricing to become life sciences superpower, says GSK boss
PositiveFinancial Markets

GSK's CEO Emma Walmsley has highlighted the urgent need for the UK to reform its drug pricing system to enhance its position as a life sciences leader. With shares rising due to increased profits, Walmsley remains optimistic about resolving the ongoing standoff with the NHS, which is considering proposals to boost spending on new medicines by up to 25%. This reform is crucial not only for the pharmaceutical industry but also for ensuring that patients have access to innovative treatments, ultimately benefiting public health and the economy.
— Curated by the World Pulse Now AI Editorial System













